| Net loss | -12.55M |
| Depreciation | 60.06K |
| Gain on disposal of property and equipment | |
| Stock-based compensation expense | 3.46M |
| Change in fair value of marketable securities | |
| Change in fair value of rights to sell ARS to UBS | |
| Other receivables | 0 |
| Prepaids and other current assets | |
| Accounts payable | -2.48M |
| Accrued liabilities | 275.11K |
| Accrued facility exit costs | |
| Net cash used in operating activities | |
| Purchases of investments | |
| Sales of investments | |
| Maturities of investments | |
| Proceeds from sale of property and equipment | |
| Net cash provided by investing activities | |
| Payments under financing arrangement | |
| Proceeds from issuance of common stock | 8.57M |
| Net cash provided by (used in) financing activities | |
| Net decrease in cash and cash equivalents | 2.86M |
| Cash and cash equivalents at beginning of period | 4.08M |
| Cash and cash equivalents at end of period | 6.94M |
| Interest paid | |